European mid-market private equity firm Inflexion has agreed to sell its investment in European LifeCare Group, a vaccinations provider in Europe, to a European private equity group.
European LifeCare Group operates 84 specialist vaccination clinics across Denmark, UK, Netherlands, and Sweden providing a range of vaccination services including travel vaccinations, general health vaccinations, as well as mass immunisation programmes.
For over 20 years, ELCG has been a preferred partner for the delivery of public vaccination programmes for the Danish and UK NHS. In recent years, the company has expanded its services to include supporting vaccine clinical trials for leading pharmaceutical companies, partnering with industry leaders such as Sanofi and Pfizer.
Inflexion supported ELCG’s transformation from a travel vaccination provider into a leading preventative healthcare platform with a footprint across Northern Europe. With Inflexion’s backing, ELCG’s management team capitalised on the growing demand for vaccination services, delivering strong organic growth through its direct-to-consumer marketing and trusted reputation with public healthcare systems.
Inflexion supported the founder-led succession and strengthened the management team, including key leadership appointments. The business also leveraged Inflexion’s Digital team to enhance its digital marketing strategy.
Under Inflexion’s ownership, ELCG completed four acquisitions and successfully expanded into the Benelux and Swedish markets, nearly tripling its revenue over the period. The number of clinics increased by 65%, the total number of employees grew sixfold, and the total number of vaccinations delivered rose fourteenfold to over 3 million annually.
